Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

Direct-acting antivirals (DAAs) are modern treatments for chronic hepatitis C infection, but majority of available evidence on its treatment effect covers genotypes 1 to 4. Therefore, the efficacy and safety of DAAs for genotypes 5 and 6 need to be analysed. Studies were identified from Medline, Sco...

Full description

Bibliographic Details
Main Authors:	Ong The Due, Usa Chaikledkaew, Anne Julienne M. Genuino, Abhasnee Sobhonslidsuk, Ammarin Thakkinstian
Format:	Article
Language:	English
Published:	Hindawi Limited 2019-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2019/2301291

Similar Items

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
by: Thanthima Suwanthawornkul, et al.
Published: (2015-01-01)

Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis
by: Lancharat Chuncharunee, et al.
Published: (2019-08-01)

Health-related quality of life and happiness within an internal medicine residency training program: a longitudinal follow-up study
by: Abhasnee Sobhonslidsuk, et al.
Published: (2015-02-01)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019-11-01)

Clinical Outcomes after Liver Transplantation for Hepatorenal Syndrome: A Systematic Review and Meta-Analysis
by: Piyapon Utako, et al.
Published: (2018-01-01)

Comparing the Efficacy of Direct Acting Antiviral Agents for the Treatment of Hepatitis C Virus Genotype 1
by: Ali, Rahma, et al.
Published: (2016)

Efficacy and safety of direct-acting antivirals for treatment of hepatitis C infected kidney transplant recipients; a meta-analysis
by: Wisit Cheungpasitporn, et al.
Published: (2017-04-01)

Corticosteroid and antiviral therapy for Bell's palsy: A network meta-analysis
by: Attia John, et al.
Published: (2011-01-01)

Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
by: Yong-yu Mei, et al.
Published: (2020-01-01)

Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
by: Elena Laura Iliescu, et al.
Published: (2020-01-01)

The efficacy and safety of direct-acting antiviral drugs in the management of hepatitis C virus-related arthritis
by: Samah M. Alian, et al.
Published: (2020-09-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
by: Ming V Lin, et al.
Published: (2016-01-01)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020-03-01)

Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan
by: Kao-Chi Chang, et al.
Published: (2021-06-01)

The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study
by: Seong Jun Park, et al.
Published: (2018-10-01)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
by: Bader Faiyaz Zuberi
Published: (2017-08-01)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
by: Yu‐Jun Wong, et al.
Published: (2019-06-01)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
by: Chao Shen, et al.
Published: (2020-12-01)

High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C
by: Mai Abozeid, et al.
Published: (2018-10-01)

The efficacy and safety of antiviral drugs of direct action in liver recipients with recurrence of chronic hepatitis C genotype 1 after transplantation
by: О. M. Tsiroulnikova, et al.
Published: (2019-01-01)

Preventive Role of Diet Interventions and Dietary Factors in Type 2 Diabetes Mellitus: An Umbrella Review
by: Phung Lam Toi, et al.
Published: (2020-09-01)

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy
by: Daniel Melendez-Mena, et al.
Published: (2021-09-01)

Adverse effects, drug interactions, and safety of direct-acting antiviral agents in treatment of hepatitis C
by: ZHAO Xitai, et al.
Published: (2017-06-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01)

Safety and efficacy of direct-acting antiviral drugs in the treatment of chronic hepatitis C virus infection in patients with thalassemia: a prospective study
by: Elsayed Ghoneem, et al.
Published: (2021-06-01)

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis
by: Ki Tae Yoon
Published: (2016-10-01)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
by: Tag-Adeen M, et al.
Published: (2017-10-01)

Features of Treatment of Patients Infected with Hepatitis C Virus Genotypes 1 And 4 by Direct-Acting Antiviral Drugs
by: V.P. Shypulin, et al.
Published: (2016-09-01)

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
by: Ezequiel Ridruejo, et al.
Published: (2020-01-01)

Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
by: Ezequiel Ridruejo, et al.
Published: (2020-01-01)

Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis
by: HOU Yihui
Published: (2020-01-01)

Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis
by: Liwei Zhuang, et al.
Published: (2021-07-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Mexican experience with direct-acting antivirals in the treatment of hepatitis C
by: J.L. Pérez Hernández, et al.
Published: (2020-09-01)

Refractory Hepatic Hydrothorax in Chronic Hepatitis C Controlled by Direct-acting Antivirals
by: Myung Hee Kim, et al.
Published: (2020-02-01)

Efficacy of direct-acting antiviral therapy for hepatitis C viral infection. Real-life experience in Bahrain
by: Abdulla M, et al.
Published: (2019-05-01)

Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania
by: Iosif Marincu, et al.
Published: (2021-09-01)